Clinical Trials List
Protocol NumberVersion1 2022/05/27
2022-01-01 - 2025-12-31
Phase II
Recruiting2
ICD-10C61
Malignant neoplasm of prostate
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9185
Malignant neoplasm of prostate
-
Trial Applicant
-
Sponsor
-
Trial scale
Taiwan Single Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- I-hung Shao Division of Hematology & Oncology
- Hong-Cheng Gan Division of Hematology & Oncology
- Kung-Chu Ho Division of Nuclear Medicine
- Ming-Li Hsieh Division of Urology
- 許毓昭 Division of Urology
- Chih-Te Lin Division of Urology
- 曹書瀚 Division of Urology
- Rita cheng Division of Hematology & Oncology
- Gigin Lin Division of Radiology
- 林宇旌 Division of Radiology
- Shih-Tsung Huang Division of Urology
- 張博誌 Division of Urology
- 陳建綸 Division of Urology
- 吳俊德 Division of Hematology & Oncology
- Kai-Jie Yu Division of Hematology & Oncology
- 陳東藝 Division of Cardiovascular Diseases
- Shao-Wei Chen Division of Cardiovascular Surgery
- 陳煜 Division of Urology
- 王敘涵 Division of Urology
- Chen Pang Hou Division of Urology
- PO-HUNG LIN Division of Hematology & Oncology
- Chang-Fu Kuo Division of Rheumatology
- Jing-Ren Tseng Division of Nuclear Medicine
- 黃信介 Division of Urology
- 林國仁 Division of Urology
- 楊佩珊 Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Principal Investigator
Co-Principal Investigator
- Yeong-Shiau Pu Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
1200 participants
-
Global
0 participants
